Notice2026-03337
Prospective Grant of an Exclusive Patent License: In Vivo Manufactured Anti-CD19 Chimeric Antigen Receptor (CAR) Products for the Treatment or Prevention of B Cell Mediated Autoimmune Diseases
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
February 20, 2026
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Abstract
The Department of Health and Human Services, National Institutes of Health published a Notice in the Federal Register on August 5, 2025. That notice requires a correction in the SUPPLEMENTARY INFORMATION section.
Full Text
<html>
<head>
<title>Federal Register, Volume 91 Issue 34 (Friday, February 20, 2026)</title>
</head>
<body><pre>
[Federal Register Volume 91, Number 34 (Friday, February 20, 2026)]
[Notices]
[Pages 8261-8262]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2026-03337]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive Patent License: In Vivo
Manufactured Anti-CD19 Chimeric Antigen Receptor (CAR) Products for the
Treatment or Prevention of B Cell Mediated Autoimmune Diseases
AGENCY: National Institutes of Health, HHS.
ACTION: Notice; correction.
-----------------------------------------------------------------------
SUMMARY: The Department of Health and Human Services, National
Institutes of Health published a Notice in the Federal Register on
August 5, 2025. That notice requires a correction in the SUPPLEMENTARY
INFORMATION section.
DATES: Only written comments and/or applications for a license which
are received by the National Cancer Institute's Technology Transfer
Center on or before March 9, 2026 will be considered.
ADDRESSES: Inquiries and comments relating to the contemplated
Exclusive Patent License should be directed to: Andrew Burke, Ph.D.,
Senior Technology Transfer Manager, NCI Technology Transfer Center,
Telephone: (240)-276-5484; Email: <a href="/cdn-cgi/l/email-protection#73121d170a5d1106011816331d1a1b5d141c05"><span class="__cf_email__" data-cfemail="3859565c41165a4d4a535d78565150165f574e">[email protected]</span></a>.
SUPPLEMENTARY INFORMATION:
Correction
In the Federal Register of February 13, 2026, in FR Doc. 2026-
02907, on page 6864, as found within the SUPPLEMENTARY INFORMATION
section. Currently reads:
``The development, production, and commercialization of an anti-
CD19 targeting chimeric antigen receptor (CAR)-based immunotherapy
using a:
1. non-viral synthetic nanoparticle-based system, or
2. viral system (excluding lentiviral)
that encapsulates mRNA or DNA encoding a CAR having the complementary
determining region (CDR) sequences of the anti-CD19 scFv known as Hu19,
for the treatment or prevention of autoimmune diseases. And is
corrected to read:
``The development, production, and commercialization of an anti-
CD19 targeting chimeric antigen receptor (CAR)-based immunotherapy
using a:
3. non-viral synthetic nanoparticle-based system, or
4. viral system
that encapsulates mRNA or DNA encoding a CAR having the complementary
determining region
[[Page 8262]]
(CDR) sequences of the anti-CD19 scFv known as Hu19, for the treatment
or prevention of autoimmune diseases.
Alycia Booth,
NIH Federal Register Certifying Official, National Institutes of
Health.
[FR Doc. 2026-03337 Filed 2-19-26; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on February 20, 2026.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.